Effects of mangesium salts and their combination with vitamin B6 on oxalates crystalluria in alimentary deficiency of piridoxine


Cite item

Full Text

Abstract

We studied the effects of oral magnesium (Mg) salts either alone or in combination with pyridoxine hydrochloride in rats on pyridoxine-deficient diet. Fifty-four male rats were randomized into two groups and were fed either a standard diet or a pyridoxine-deficient diet for 3 weeks. A significant rise of the EGOT index ( > 1.5), oxaluria (from 74.8 ± 5.2 to 117.9 ± 12.3 mcM/l, p = 0.035), and crystalluria in rats fed with pyridoxine deficient diet were revealed. Oral Mg chloride, Mg L-aspartate either alone or in combination with pyridoxine in comparison with magnesium sulfate, magne B6 (Mg lactate with pyridoxine) and pyridoxine alone were administered (50 mg of magnesium and/or 5 mg of pyridoxine per kg body weight). Magnesium salts in combination with pyridoxine lowered an oxalate level and crystalluria whereas magnesium salts alone reduced only crystalluria. Antilithis effects of Mg L-aspartate and Mg chloride in combination with pyridoxine were comparable with those observed in magne B6 or pyridoxine treatment and were significantly higher than in magnesium sulfate treatment.

References

  1. Гурвич Д. Б., Коровина Н. А., Мырсова Л. И. Влияние диеты, обогащенной магнием, на экскрецию оксалатов и функциональное состояние почек у больных с гипероксалурией. Педиатрия 1979; 2: 14-16.
  2. Prien E. L., Gershoff S. N. Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi. J. Urol. (Baltimore) 1974; 112: 509.
  3. Firoz M., Graber M. Bioavailability of US commercial magnesium preparations. Magnes. Res. 2001; 14 (4): 257-262.
  4. Iezhitsa I. N., Spasov A. A., Kravchenko M. S. et al. Comparative study of magnesium salts' bioavailability in rats fed with magnesium-deficient diet. J. Jpn. Soc. Magnes. Res. 2006; 25 (2): 99.
  5. Сивориновский Г. А. Количественное определение щавелевой кислоты в моче. Лаб. дело 1969; 7: 401-404.
  6. Меньшиков В. В., Делекторская Л. Н., Золотнинская Р. М. Лабораторные методы исследования в клинике: Справочник. М.: Медицина; 1987. 266-267.
  7. Allegra A., Corica F., Ientile R. et al. Plasma (total and ionized), erythrocyte and platelet magnesium levels in renal transplantant recipients during cyclosporine and/or azathioprine treatment. Magnes. Res. 1998; 11 (1): 11-18.
  8. Garsia-Rodriguez M. B., Peres-Garsia C. C., Rios-Granja M. A. et al. Renal handling of calcium and phosphorus in experimental renal hyperparathyroidism in dogs. Vet. Res. 2003; 34: 379-387.
  9. Рыбина И. Л., Вощула В. И. Оценка роли метаболизма оксалата в этиопатогенезе мочекаменной болезни. БМЖ. 2006; 1: 15.
  10. Leklem J. E. Vitamin B-6: A status report. J. Nutr. 1990; 120 (11S): 1503-1507.
  11. Monico C. G., Persson M., Ford G. C. et al. Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II. Kidney Int. 2000; 62 (2): 392-400.
  12. Cochat P., Liutkus A., Fargue S. et al. Primary hyperoxaluria type 1: till challenging! Pediatr. Nephrol. 2006; 21 (8): 1075-1081.
  13. Khan S. R., Shevock P. N., Hackett R. L. Magnesium oxide administration and prevention of calcium oxalate nephrolithiasis. J. Urol. (Baltimore) 1993; 149: 412-416.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies